JAAD onlineReply to: “Use of immortal time within survival analysis”
References (2)
- et al.
Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study
J Am Acad Dermatol
(2018) - et al.
Use of immortal time within survival analysis
J Am Acad Dermatol
(2019)
Cited by (0)
Funding sources: Supported by Stanford Medical Scholars Research Program (to Mr Lee). Stanford Cancer Institute Research Database (SCIRDB) is funded by a National Cancer Institute Cancer Center support grant (no. 5P30CA124435) and Stanford National Institutes of Health/National Center for Research Resources Clinical and Translational Science Award (no. UL1 RR025744).
Conflicts of interest: Dr Chang is a clinical investigator and advisory board member for Merck and Regeneron. All other authors do not have any conflicts of interested to disclose.
© 2018 by the American Academy of Dermatology, Inc.